# A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

> **NCT02580058** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 566 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** avelumab
- **DRUG:** PLD

## Key facts

- **NCT ID:** NCT02580058
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2018-09-19
- **Final completion:** 2022-07-12
- **Target enrollment:** 566 (ACTUAL)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580058, "A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02580058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*